key: cord-0726823-4zsk9iat
authors: Mills, Richard J.; Humphrey, Sean J.; Fortuna, Patrick RJ.; Lor, Mary; Foster, Simon R.; Quaife-Ryan, Gregory A.; Johnston, Rebecca L.; Dumenil, Troy; Bishop, Cameron; Ruraraju, Rajeev; Rawle, Daniel J.; Le, Thuy; Zhao, Wei; Lee, Leo; Mackenzie-Kludas, Charley; Mehdiabadi, Neda R.; Halliday, Christopher; Gilham, Dean; Fu, Li; Nicholls, Stephen J.; Johansson, Jan; Sweeney, Michael; Wong, Norman C.W.; Kulikowski, Ewelina; Sokolowski, Kamil A.; Tse, Brian W.C.; Devilée, Lynn; Voges, Holly K.; Reynolds, Liam T.; Krumeich, Sophie; Mathieson, Ellen; Abu-Bonsrah, Dad; Karavendzas, Kathy; Griffen, Brendan; Titmarsh, Drew; Elliott, David A.; McMahon, James; Suhrbier, Andreas; Subbarao, Kanta; Porrello, Enzo R.; Smyth, Mark J.; Engwerda, Christian R.; MacDonald, Kelli PA.; Bald, Tobias; James, David E.; Hudson, James E.
title: BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection
date: 2021-03-16
journal: Cell
DOI: 10.1016/j.cell.2021.03.026
sha: f1ca8fcafd19ff9c50fd802ad11f2f4c38752877
doc_id: 726823
cord_uid: 4zsk9iat

Cardiac injury and dysfunction occur in COVID-19 patients and increase the risk of mortality. Causes are ill defined, but could be direct cardiac infection and/or inflammation-induced dysfunction. To identify mechanisms and cardio-protective drugs, we use a state-of-the-art pipeline combining human cardiac organoids with phosphoproteomics and single nuclei RNA sequencing. We identify an inflammatory ‘cytokine-storm’, a cocktail of interferon gamma, interleukin 1β and poly(I:C), induced diastolic dysfunction. Bromodomain-containing protein 4 is activated along with a viral response that is consistent in both human cardiac organoids and hearts of SARS-CoV-2 infected K18-hACE2 mice. Bromodomain and extraterminal family inhibitors (BETi) recover dysfunction in hCO and completely prevent cardiac dysfunction and death in a mouse cytokine-storm model. Additionally, BETi decreases transcription of genes in the viral response, decreases ACE2 expression and reduces SARS-CoV-2 infection of cardiomyocytes. Together, BETi, including the FDA breakthrough designated drug apabetalone, are promising candidates to prevent COVID-19 mediated cardiac damage.

SARS-CoV-2 infection leads to cardiac injury and dysfunction in 20-30% of hospitalized patients 2 (Guo et al., 2020) and higher rates of mortality in patients with pre-existing cardiovascular 3

disease (Shi et al., 2020; Wu and McGoogan, 2020) . The cardiac sequelae reported in patients 4

with COVID-19, include acute coronary syndromes, cardiomyopathy, acute pulmonary heart 5 disease, arrhythmias and heart failure (Gupta et al., 2020) . Furthermore, 68-78% have 6 sustained cardiac dysfunction, primarily right ventricle dysfunction and left ventricular diastolic 7

dysfunction (Puntmann et al., 2020; Szekely et al., 2020 ). Yet clear mechanistic insight is 8 currently lacking. 9

In the absence of infection, well known inflammatory mediators such as TNF are associated 10 with heart failure and have been demonstrated to induce systolic dysfunction (Feldman et al., 11 2000) . Therefore, severe inflammation may play a key role in cardiac injury and dysfunction 12 . In support of this, there is a severe inflammatory response in 5% of COVID- 13 19 patients associated with septic shock (Wu and McGoogan, 2020) . Due to the septic shock 14 and drop in blood pressure, approximately 30% of hospitalized patients with COVID-19 require 15

vasopressors to improve blood pressure (Goyal et al., 2020) . Mediating these responses in 16 some patients is a cytokine storm of similar magnitude to that induced by CAR-T cell-associated 17 cytokine storms (Del Valle et al., 2020) . Additionally, severe COVID-19 is associated with sepsis 18 and bacterial products in the serum (Arunachalam et al., 2020) , which are known drivers of 19 cardiac pathology and dysfunction. Cardiac dysfunction may also result in further exacerbation 20 of infectious diseases, via inadequate organ perfusion and/or immune cell infiltration. Thus, 21

preventing cytokine-induced cardiac dysfunction may potentially limit severe outcomes in 22 inflammatory diseases. However, targeted treatment strategies, particularly in severe infections 23 such as COVID-19, are currently lacking. immunosuppression may impede viral clearance thus potentially exacerbating disease 28 (Mangalmurti and Hunter, 2020) . To circumvent this, we aimed to identify cardiac-specific 29 inflammatory targets that trigger cardiac dysfunction in response to the cytokine storm, 30 reasoning that these might provide a safe and effective therapeutic option. 31

Here, we utilize multi-cellular human pluripotent stem cell (hPSC)-derived cardiac organoids 32

(hCO) combined with phosphoproteomics and single nuclei RNA-sequencing (RNA-seq) to 33 identify therapeutic targets and treatments for cardiac dysfunction. We recently adapted our 34 hCO system (Mills et al., 2019; Mills et al., 2017a) to include co-culture with endothelial cells 35 that form enhanced branched endothelial structures surrounded by pericytes ( Figure S1A , 36 Voges et al., In Revision). This protocol results in a complex mixture of self-organising cells 37 including epicardial, fibroblasts/pericytes, endothelial cells and cardiomyocytes. This was 38

combined together with an optimized culture environment that reflects a maturation stage; 

We began by examining the effects of a range of pro-inflammatory cytokines elevated in 3 COVID-19 patients (Huang et al., 2020) on cardiac function in our hCO (Mills et al., 2017a ). 4

Inflammatory molecules tested were likely candidates in COVID-19 including: TNF, IL-1β, IFN-γ, 5

IL-6, IL-17A, and G-CSF, as well as pathogen-associated molecular patterns including poly(I:C) 6

to mimic dsRNA, and lipopolysaccharide (LPS) to mimic TLR4 activation and septic responses. 7

Using our RNA-seq data (Mills et al., 2017a) , we identified that the receptor genes IL1R1, 8 TNFRSF1A, TNFRSF1B, IFIH1, MYD88, IL6ST, IFNAR1, IL6R, TMEM173, IL17RA, IL17RB, 9

IL17RC, IL17RD, IL17RE, IFNGR1, TLR3, and TLR4 were expressed at similar or higher 10 abundance in our hCO compared to adult human heart ( Figure S1B ). In adult mouse hearts 11 many of these are enriched in non-myocyte populations (Quaife-Ryan et al., 2017) ( Figure  12 S1C). We used single nuclei RNA sequencing (snRNA-seq) to assess cell specificity in our 13 enhanced hCO (Voges et al., In Revision) . Mapping to human heart snRNA-seq (Tucker et al., 14 2020) revealed the presence of pro-epicardial/epicardial cells, fibroblasts, activated 15 fibroblasts/pericytes and cardiomyocytes ( Figure S1D ,E). Some cardiomyocytes were fetal-like, 16 however there was a distinct sub-cluster that mapped adjacent to adult ventricular 17 cardiomyocytes from human hearts (Gilsbach et al., 2018) ( Figure S1F ). The cytokine/pro-18

inflammatory receptors were expressed in the different cell types and were more highly 19 expressed in epicardial cells and fibroblasts ( Figure S1G) . We screened inflammatory factors in 20

all pair-wise combinations in hCOs with multiple functional measurements including contractile 21

force, rate, activation kinetics and relaxation kinetics ( Figure 1A) . TNF caused a reduction in 22 force, while IL-1β, IFN-γ, poly(I:C) and LPS caused diastolic dysfunction characterized by a 23 preserved contractile force but prolonged time from peak to 50% relaxation ( Figure S2A to E). 24 A secondary full-factorial screen of TNF, IFN-γ, IL-1β, and poly(I:C), once again revealed that 25 TNF induced systolic dysfunction ( Figure 1B,D) with a EC 50 of 1 ng/mL at 48 hours ( Figure  26 S2F). A combination of IL-1β, IFN-γ and poly(I:C) induced diastolic dysfunction ( Figure 1C ,E), 27 however also decreased the beating rate which may influence the kinetics of contraction 28

( Figure S3A , Supplementary Video 1,2). Changes in rate were not responsible for increased 29 relaxation time, as hCO paced at 1 Hz retained the severe diastolic dysfunction phenotype 30

( Figure 1F, Supplementary Video 3,4) . Individually, IFN-γ and IL-1β caused concentration-31 dependent diastolic dysfunction with an EC 50 of 0.8 ng/mL at 48 hours and 3 ng/mL at 24 hours, 32

respectively, whereas poly(I:C) alone did not induce dysfunction ( Figure S2G to I). These 33 results were confirmed in an independent hPSC line, where the combination of IFN-γ, IL-1β and 34

poly(I:C) induced the most consistent, robust diastolic dysfunction (Figure S3A to E). Taken  35 together, TNF induces systolic dysfunction consistent with previous in vitro (Vasudevan et al., 36 2013) and in vivo (Kubota et al., 1997 ) studies, and the combination of IFN-γ, IL-1β and 37

poly(I:C) induces severe diastolic dysfunction in hCO. The dominant factor identified that causes 38 diastolic dysfunction, IFN-γ ( Figure S3C) , is generally elevated in heart failure patients but with 39 contradictory effects in animal models (Levick and Goldspink, 2014) . 40

The most common types of cardiac dysfunction observed in hospitalized COVID-19 patients are 42 right ventricular dysfunction or left ventricular diastolic dysfunction (Szekely et al., 2020) . 43 Therefore, we focussed on diastolic dysfunction induced by IFN-γ, IL-1β and poly(I:C), we refer 44 J o u r n a l P r e -p r o o f to as 'cardiac cytokine storm' (CS). Protein phosphorylation is linked with all biological functions 1 (Needham et al., 2019) , and thus we measured the global phosphoproteome in hCO. 2 Leveraging our latest phosphoproteomics technology (Humphrey et al., 2015; Humphrey et al., 3 2018), we identified over 7,000 phosphosites in each sample. We accurately pinpointed 7,927 4 phosphorylation sites to a single amino acid residue on ~3,000 different phosphoproteins from 5 single-run measurements (Figure 2A) . Preliminary studies on TNF treated hCO identified 6 several known effects including decreased phosphorylation of protein kinase A and increased 7 phosphorylation of beta-adrenergic receptor kinase 1 (also known as GRK2), supporting our 8 approach (data not shown). CS treatment induced 91 phosphosites that were consistently 9 elevated ( Figure 2B ). These sites were enriched for transcriptional responses with 35 sites 10 found on transcription factors or chromatin-binding proteins and 13 associated with the 11 biological process term 'cell proliferation' (FDR < 0.05, Fisher's exact test). Among these was 12 phosphorylation of signal transducer and activator of transcription 1 (STAT1) S727 (median 13.9 13

fold), as well as two sites on BRD4 (Bromodomain-containing protein 4) S469 and S1083 14 (median 7.4 and 12.3 fold respectively) ( Figure 2B,C) . In light of the availability of specific small 15 molecule inhibitors for each of these targets or their upstream regulators, we focused on these 16

proteins in subsequent functional assays. 17

We assessed activation of individual cell populations in hCOs using snRNA-seq ( Figure 3A ) 18 with mapping as described above (CTRL - Figure S1D ,E and CS - Figure S4A ,B). In the CS 19

condition there was an increase in fibroblast and activated fibroblast number ( Figure 3B ). 20 KEGG pathway analysis revealed a transcriptional response dominated by a viral response in 21 both cardiomyocytes (CM1, CM2 and CM3 pooled) and fibroblasts (epicardial/fibroblast and 22

perictye/activated fibroblasts) (Figure 3C ,D). There were fewer downregulated genes, which 23

were predominantly in the fibroblasts and dominated by extracellular matrix (ECM) genes 24

including COL1A1, COL3A1 and COL4A5 ( Figure 3E ). The top predicted mediators of the 25 transcriptional response were STAT1 and general epigenetic activation by EP300 ( Figure 3F ). 26 This is consistent with our phosphoproteomic data (Figure 2 ), given EP300 has been shown to 27

share upto 78% of DNA binding regions with BRD4 in chromatin immunprecipitation studies 28 (Williams et al., 2020) . These analyses together revealed a robust viral response in the heart in 29 multiple cell populations ( Figure 3G,H) , predicted to be mediated via STAT1 and epigenetic 30 activation including BRD4. 31

We next screened drugs that could potentially treat cardiac dysfunction caused by either TNF-33

induced systolic dysfunction or CS-driven diastolic dysfunction ( Figure 4A ). TNF is known to 34

induce systolic dysfunction via GRK2 mediated repression of β-adrenergic receptor signaling 35 (Vasudevan et al., 2013) . The selective serotonin reuptake inhibitor, paroxetine hydrochloride, 36

can inhibit GRK2 (Schumacher et al., 2015) , but we found that it was toxic at effective in vitro 37

concentrations (Guo et al., 2017) ( Figure S5A,B) . GRK2 promotes clathrin-mediated 38 endocytosis (Evron et al., 2012), and baricitinib was recently identified as a potential AP2-39 associated protein kinase 1 (AAK1)-mediated endocytosis inhibitor using machine learning 40 (Richardson et al., 2020) . Baricitinib prevented TNF-induced dysfunction in hCO ( Figure 4B and 41 Figure S5A ,B). However, baricitinib was only protective against TNF-induced systolic 42 dysfunction when co-administered with TNF and was not effective after 24 h TNF treatment 43 ( Figure 4C) . Additionally, hCO did not recover quickly from TNF-induced systolic dysfunction 44

after the removal of TNF ( Figure 4C) indicating that secondary remodeling events may have 45 occurred. 46

A key signature of diastolic dysfunction under CS conditions was the elevated phosphorylation 1 of transcriptional regulators. STAT1-S727 ( Figure 2C ) is associated with assembly into 2 chromatin and is required for STAT1 transcriptional and biological activity in response to IFN-γ 3 (Sadzak et al., 2008) . The putative STAT1-S727 kinase is CDK8 (Bancerek et al., 2013) , so we 4 next tested two CDK8 inhibitors SEL120-34A (Rzymski et al., 2017) and BI-1347 (Hofmann et  5 al., 2020) previously shown to reduce STAT1-S727 phosphorylation. We also tested two 6

inhibitors of the JAK/STAT pathway, baricitinib and ruxolitinib. However, none of these 7

compounds, nor a broader spectrum CDK inhibitor flavopiridol, prevented the CS-induced 8 diastolic dysfunction, noting that flavipiridol was toxic and reduced force and hence all kinetic 9

parameters (Figure S6A to H) . Notably, SEL120-34A and BI-1347 specifically attenuated the 10 rate and activation time defects under CS conditions ( Figure S6B ,C,F,G), which we validated in 11

additional experiments (Figure S5C to F) and may still have clinical utility in this setting. 12

We observed elevated phosphorylation of the epigenetic regulator BRD4 and other epigenetic 13 regulators in our CS treated hCO phosphoproteome, consistent with our snRNA-seq analysis. 14 We have previously shown that bromodomain extraterminal inhibitors (BETi) reduce relaxation ~74% knockdown could also reduce diastolic dysfunction in CS treated hCO ( Figure S5K ). 28

INCB054329-mediated BETi rescued dysfunctional hCO, and restored diastolic function 29

following 24 h of CS conditions ( Figure 4E ). This is potentially because CS-induced diastolic 30 dysfunction is reversible and is driven by the presence of the inflammatory mediators, 31 demonstrated by partial hCO recovery 24 h after removing CS factors ( Figure 4E ). In patients, 32

all inflammatory factors may be present simultaneously, and we found that INCB054329  33  attenuated diastolic dysfunction with all four dysfunction inducing factors, TNF, IFN-γ, IL-1β, and  34 poly(I:C), present ( Figure S5J ). Taken together CS mediates diastolic dysfunction via BRD4-35 dependent mechanisms that can be blocked using BETi. As BRD4 is broadly expressed in our 36 hCO (Figure 4F) , it may also be responsible for the multi-cellular response observed. 37

We next assessed the response to SARS-CoV-2 infection in vivo. As mice are not susceptible to 40 SARS-CoV-2 infection, we used a recently described K18-hACE2 model (Oladunni et al., 2020) 41 to study the response and effects of BETi ( Figure 5A ). SARS-CoV-2 infected mice had severe 42 lung pathology and substantial viral RNA reads in the lungs at 4-5 days post infection. 43

confirming successful lung infection (Figure 5B,C) . RNA-seq of the lungs revealed increased 44 expression of 419 genes (Figure 5D ), strongly associated with a viral response ( Figure 5E , 45 Table S1A ). Concordant with our hCO data, Stat1 and Ep300 were top predicted transcriptional 46 regulators ( Figure 5F , Table S1B). Interestingly, there was only negligible infection of the heart 47 ( Figure 5C ) and no obvious pathology including necrosis, immune cell infiltration or fibrosis 1 ( Figure 5G ). However, there was a substantial and robust upregulation of a viral response in 2 the heart with ECM repression (Figure 5H ,I, Table S1A ) including Col1a1, Col3a1 and Col4a2. 3 This was again enriched for Stat1 and Ep300 as top predicted transcriptional regulators ( Figure  4 5J, Table S1B ), indicating a robust systemic response in the hearts of SARS-CoV-2 infected 5

mice. This response could be partially blocked by INCB054329 treatment with repression of 91 6 genes that were enriched for the viral response ( Figure 5K to M, Table S1A ). This response 7

was more specfic to the heart, as INCB054329 did not regulate any genes in the lungs (data not 8

shown). The repression by INCB054329 was predicted to be primarily mediated via Ep300 9

rather than Stat1 ( Figure 5N , Table S1B ). These results were further supported by Ingenuity 10

Pathway Analysis of upstream regulators revealing strong activation signatures for IFNG, poly 11

rI:rC-RNA and Stat1 in both lungs and hearts of K18-hACE2 SARS-CoV-2 infected mice, which 12

INCB054329 strongly inhibited ( Table S1C) . 13

Potentially important mediators and markers of the response were found by integrating the 14 multiple datasets. The CS induced response in the hCO (either fibroblasts or cardiomyocytes) 15 and hearts of SARS-CoV-2 infected K18-hACE2 mice shared 32 regulated genes ( Figure 5O ) 16 which were enriched for the viral response ( Figure 5P ). The consistent transcriptional program 17

in CS treated hCO (both fibroblasts and cardiomyocytes) and SARS-CoV-2 infected K18-hACE2 18 mice, that were also down-regulated genes by INCB054329 treatment in vivo revaled 5 key 19

targets. These comprise the key inflammatory genes Nmi, Tap1, B2m, Stat1 and Lgals3bp 20

( Figure 5Q ). Of particular interest is LGALS3BP (galectin-3 binding protein) as it has been 21

shown to be a top-predictor of COVID-19 severity in humans (Messner et al., 2020) and 22

therefore interrogated its expression in our subsequent models. 23

The study into the efficacy of SARS-CoV-2-related cytokine storm therapeutics on the heart in 26 vivo is technically challenging in biosafety level 3 and because the severe lung/brain infection in 27

K18-hACE2 mice causes a rapid decrease in weight and requires euthanasia ( Figure 5R ). We 28 therefore used surrogate models. 29

We used a LPS-induced cytokine storm mouse model ( Figure 6A ). LPS induced pro-30

inflammatory cytokines TNF, IL-1β and IFN-γ, which were elevated in the plasma ( Figure 6B ) 31 along with Lgals3bp in the heart ( Figure 6C ). Treatment with INCB054329 blocked the LPS-32

induced pro-inflammatory cytokine production ( Figure 6B ) and Lgals3bp induction in the heart 33 ( Figure 6C ). We observed a marked improvement in mortality, whereby all INCB054329-treated 34 mice survived after 24 h of the LPS-challenge, compared with only 25% in the control group 35

( Figure 6D ). To determine whether BETi could treat an established LPS-induced cytokine 36 storm, we delayed injection of INCB054329 1.5 h after LPS injection and assessed cardiac 37 function at 6 h ( Figure 6E ). INCB054329 fully prevented the decrease in cardiac function 38 observed after LPS injection ( Figure 6F ). Together these findings demonstrate that BETi using 39

INCB054329 has robust effects in preventing inflammatory-induced cardiac dysfunction in vivo. 40

The factors present in COVID-19 patient serum are more complex than our CS conditions. So 41

we assessed the impact of this serum on hCO ( Figure 6G, Table S2A ,B). Our most potent CS 42

factor, IFN-γ, correlates with COVID-19 disease progression and is elevated in patient serum in 43 one of the most comprehensive profiling studies to date (Ren et al., 2021) . We found that IFN-γ, 44 was higher in patients with elevated BNP as a marker of cardiac stress (> 0.3 ng/ml) but not 45

CTNI as a marker of acute injury (> 0.5 ng/ml) (Figure 6H ,I). Factors in human serum can alter 46 hCO function, as patients receiving noradrenaline as inotropic support had elevated contractile 47 force in hCO ( Figure 6J ). Diastolic dysfunction was induced in hCO by serum with elevated 1 BNP ( Figure 6J ) with no viral infection detected (data not shown) and INCB054329 could 2 prevent this response ( Figure 6K ). We also found that LGALS3BP induction could be prevented 3 by treatment with multiple BETi (Figure 6L ). 4

Collectively, these data indicate that BET inhibition with INCB054329 prevents cardiac 5 dysfunction in multiple complex inflammatory models, as well as repressing the key COVID-19 6 severity marker LGALS3BP. We confirmed previous findings using 2D cultured hPSC-cardiac cell infection studies, where 14 increasing the MOI increased the degree of cell death ( Figure S7B ). Infection with a low MOI 15 (0.01) was sufficient for viral replication and cell death over 7 days ( Figure S7C) . A 3 day pre-16

incubation of INCB054329 was sufficient to reduce ACE2 expression ~4 fold ( Figure S7D ). 17 Consequently, pre-treatment with INCB054329 reduced SARS-CoV-2 N protein expression 18

( Figure S7E ) and intracellular viral RNA ( Figure S7F ). In addition to INCB054329, the widely 19

used BETi JQ-1 reduced SARS-CoV-2 RNA ( Figure S7G ). In our SARS-CoV-2 K-18 mouse 20

infection studies INCB054329 treatment reduced endogenous Ace2 in hearts in vivo ( Figure  21 S7H). Thus, BETi also has potential to block SARS-CoV-2 infection of cardiac cells in addition 22

to preventing dysfunction. 23

We assessed the ability of all commercially available BETi compounds to prevent CS-induced 25 diastolic dysfunction in hCO. We found that all compounds prevented dysfunction except for 26

ABBV-744 ( Figure 7A ). As BETi with dual bromodomain 1 (BD1) and bromodomain 2 (BD2) 27

activities display side-effects (Gilan et al., 2020) , it is critical that we determine selectivity of the 28 response. BD2-selective drugs such as ABBV-744 and apabetalone have limited side effects. 29

Apabetalone has been used for up to 3 years in >1,700 humans at risk of cardiac disease with 30 efficacy in preventing heart failure and favourable safety profile (Nicholls et al., 2021; Ray et al., 31 2020). ABBV-744 elevated diastolic dysfunction (Figure 7A) , and we suspect its lack of efficacy 32 was due to its on-target inhibition of the androgen receptor (AR). BD2-specific efficacy was 33 confirmed using a BD2-specific molecule, RXV-2157 ( Figure 7B ) and we also confirmed 34 efficacy with the BD-2 selective apabetalone ( Figure 7A,B) . Additionally, analysis of plasma 35

from the ASSURE phase IIb clinical trial indicated that BD2-selective apabetalone reduced 36

LGALS3BP in patients with cardiovascular disease (Figure 7C ), which is a marker of COVID- 19 37 severity (Messner et al., 2020). 38

We confirmed the BD2-specificity of blocking SARS-CoV-2 infection. The BD2-specific RXV-39 2157 and BD2-selective apabetalone molecules downregulated hACE2 (Figure 7D ), which led 40

to decreased surface expression ( Figure S7I ) and SARS-CoV-2 spike protein binding ( Figure  41 S7J). These compounds also reduced SARS-CoV-2 loading ( Figure S7K, Figure 7E ,F) and 42 viral titre, including a 2.6 fold decrease in viral titre with apabetalone ( Figure 7G) . 43

Together, this demonstrates that BD2 -selective BETi drugs are lead candidates for rapid 1 clinical translation to prevent COVID-19 injury in the heart. We define CS conditions resulting in severe diastolic dysfunction with 20-50% increases in time 2

to 50% relaxation in hCO. This is consistent with ~13-18% increases in cardiomyocytes derived 3 from patients with heart failure with preserved ejection fraction (HFpEF), similar absolute 4

increases of 100-150 ms (Runte et al., 2017) . It is also consistent with diastolic dysfunction 5 reported in COVID-19 patients (Szekely et al., 2020) , indicating our hCO model recapitulates 6

key clinical features of diastolic dysfunction. 7

Our transcriptional profiling revealed a striking similarity between the inflammatory response in 8

CS treated hCO and hearts of SARS-CoV-2 infected K18-hACE2 mice. CS also elicited a more 9

pronounced transcriptional response in the fibroblasts within hCO (Figure 3C,D) . This was with 10 negligible viral infection in our models, meaning that inter-organ and intra-organ signalling 11

appears to play a key role in inflammation-induced cardiac dysfunction. It will be important to 12

decipher the systemic and intra-organ drivers of dysfunction also in other oragns, because 13

COVID-19 and many other inflammatory diseases can result in multi-organ dysfunction. 14 Our data establish BET inhibition as a viable therapeutic strategy to attenuate cytokine storm- inhibition as a therapeutic intervention to prevent cardiac dysfunction caused by inflammation. 22

Clinical data from COVID-19 patients also point to additional cardiac pathologies. Microthrombi 23

were reported in the hearts of 14 out of 40 patients (35%) that died from COVID-19, which was 24 associated with areas of myocardial necrosis (Pellegrini et al., 2021) . Consistent with these 25 observations, we observed that "complement and coagulation cascades" were enriched in the 26 lungs of K18-hACE2 mice with SARS-CoV-2 infection ( Figure 5E and Table S1 ), and were 27

likely related to the viral-induced inflammatory response. Intriguingly, we identified serpine1 28

(also known as plasminogen activator inhibitor 1), was upregulated both in the lungs (3.9 fold) 29 and in the heart (2.8 fold, both FDR < 0.05) of SARS-CoV-2 infected K18-hACE2 mice, which 30

was abrogated in the heart upon treatment with the BETi INCB054329 (FDR < 0.05). Serpine 1 31

is a key inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator, 32

and is required for fibrinolysis down-regulation and degradation of blood clots. In addition, 33

arrhythmic events have been widely reported in COVID-19 patients (Nishiga et al., 2020). 34

Indeed, we observed that arrhythmic events increased in hCO with CS, for which INCB054329 35 also conferred protection ( Figure S5L to N This underscores the need for careful BETi selection, despite broad ability to modulate critical 2 target genes ( Figure 6L ) and utility for a variety of clinical conditions (Cochran et al., 2019). 3

Importantly, BD2-selective BETi apabetalone reduced CS-induced diastolic dysfunction and 4 downregulated ACE2 and reduced viral infection (Figure 7) . Taken together, the efficacy and 5

known safety profile of apabetalone make it a prime candidate to protect against cardiac injury 6

for inflammatory diseases such as COVID-19. 7

The overlap in risk factors for HFpEF and COVID-19 mortality suggests that our findings may 8 also have broader implications. HFpEF risk factors including diabetes and obesity are also 9 associated with chronic inflammation. Recent studies have shown that elevated inflammatory 10 markers are associated with worsening heart function in HFpEF (Sanders-van Wijk et al., 2020), 11

thus indicating that inflammation may drive dysfunction across multiple cardiac diseases and 12

that BET inhibitors are putative therapeutic candidates. 13

Human COVID-19 patient serum and CS directly impacted hCO function. There is evidence that 15

the heart can be inflamed in patients with COVID-19 ( studies are required to ascertain the full extent of the inflammatory effects on heart function in 19

the clinic, in particular on diastolic function as found in some echocardiography studies (Szekely 20 et al., 2020). It will be important to determine whether cardiac inflammation and cardiac function 21 effects (which may be sub-clinical in cases) are prolonged following acute infection and whether 22

this pre-disposes patients to future risk of cardiovascular events. 23

Our hCO model is free from an active immune system and the secondary effects of 24 neurohormonal compensation present in vivo. Our hCO work, the lack of response in the lungs 25 of INCB054329 treated SARS-CoV-2 infected K18-hACE2 mice and improvement of heart 26 function with delayed INCB054329 treatment in the LPS treated mice ( Figure 6F) ; all indicate 27 robust cardiac specific effects. However, BETi within an in vivo setting may also reduce immune 28 responses and cytokine induction (eg. Figure 6B) , thus, we cannot rule this out as a potential 29 mechanism for cardiac protection in mouse studies. In order to elucidate cardiac specific effects, 30

genetic studies may be useful. However, these may be difficult because 1) BRD4 knockout has 31 different effects to small molecule inhibitors (Kim et al., 2020; Padmanabhan et al., 2020) and 2) 32

BETi drugs bind multiple BRD family members, which may be more potent that targeting one 33 member (Gilan et al., 2020). Therefore, further mechanistic insight into the key transcriptional 34

targets of BET proteins is important. These targets could then be manipulated using cardiac 35 specific-genetic approaches to validate cardiac specificity of BETi. However, the feasibility of 36 this approach will be dependent on the number of targets that are critical for BETi efficacy, as 37 multiple targets may require genetic manipulation simultaneously. Nigel Waterhouse (QIMR Berghofer) for microscopy. Nadine Shultz and Paul Collins (QIMR 7

Berghofer) for the sequencing and Scott Wood, Pamela Mukhopadhyay, John Pearson, Nic 8

Waddell and Ross Koufariotis for (QIMR Berghofer) bioinformatics assistance. Ben Crossett, 9

Angela Connolly, and Jens Altvater (University of Sydney) for mass spectrometry assistance. 10

Compounds Australia (www.compoundsaustralia.com) for providing access to compounds. 11

Edouard Stanley (Murdoch Children's Research Institute) for the RM3.5 iPSC line. Translational 12

Research Institute for Preclinical Imaging and Biological Resources Facility. Sydney Mass 13

Spectrometry core research facility at the University of Sydney. genes regulated by the transcription factor/number of genes regulated, and % of genes 47

regulated over the total. The size of the coloured slices represent the fraction of genes regulated 48 (180° = 100%), and overlaps for each transcription factor are also depicted. Additional data 1 bioinformatics analysis is provided in Table S1A to C. or compared to CS (L), or using two-way ANOVA with Sidak's multiple comparisons test (F), or 30

using Mann-Whitney (I). P-value calculated using Gehan-Breslow-Wilcoxon test (D).Additional 31 data patient data is provided in Table 2 S2A,B. 32 with Dunnett's multiple comparisons test comparing each condition to CTRL at comparable 10 time point. n= 2-5 human cardiac organoids for treatments, n= 7-9 human cardiac organoids 11

for CTRL from 1 experiment. Data are presented as mean ± SEM. Human pluripotent stem 12

cell-derived cardiac cells-AA line. Endothelial cells-RM3.5 line. 13

presence/absence) with time from peak to 50% relaxation as the outcome variable at 24 15 h. Coefficients represent the mean change in the response given one unit change in the 16

predictor. Sign of the coefficient represents the direction of the change between 17

predictor and response. Overall, presence of IFN-γ, IL-1β, poly(I:C) all lead to increased 18 relaxation times whilst presence of TNF leads to a reduced relaxation. * p <0.05, ** 19

p<0.01, **** p<0.0001 using regression modelling. 

Further information and requests for resources and reagents should be directed to and will be 4 fulfilled by the lead contact, James E Hudson james.hudson@qimrberghofer.edu.au 5

This study did not generate new unique reagents except for RVX-2157 for which requests 7

should be addressed to Resverlogix. 8 Committee -Project 182/20). Individuals consented to provide additional blood that was 4 processed within 24 h of collection for plasma and peripheral blood mononuclear cells. Whole 5

blood was centrifuged at 1000 x g for 10 min at 22°C-24°C then plasma removed within 5 mm of 6 the buffy coat. Plasma aliquots were transferred to 2 ml cryovials for long term storage at -7

80°C. Plasma was thawed and immediately use for ELISA for CTNI, IFN-γ and BNP. Calcium 8 was added to 10 mM to normalize calcium levels of citrated plasma and clot. The supernatant 9

was removed (serum) and used for the hCO experiments (50% serum/50% WM). No viral RNA 10 was detected in hCO treated with human COVID-19 serum. 11

The design and rationale of the ASSURE trial (ClinicalTrials.gov identifier NCT01067820) is EDTA plasma samples were analysed using SOMAScan TM . 16 

Cardiac differentiation was performed as previously described (Hudson et Penicillin/Streptomycin (ThermoFisher Scientific), supplemented with 5 ng/ml BMP-4 (RnD 1 Systems), 9 ng/ml Activin A (RnD Systems), 5 ng/ml FGF-2 (RnD Systems) and 1 µM 2 CHIR99021 (Stem Cell Technologies). Mesoderm induction required daily medium exchanges 3 for 3 days. This was followed by cardiac specification using RPMI B27-containing 5 µM IWP-4 4 (Stem Cell Technologies) for another 3 days, and then further 7 days using 5 µM IWP-4 RPMI 5 B27+ (RPMI1640 Glutamax + 2% B27 supplement with insulin, 200 µM L-ascorbic acid 2-6 phosphate sesquimagnesium salt hydrate and 1% Penicillin/Streptomycin) with media change 7 every 2-3 days. For the final 2 days of differentiation, hPSCs were cultured in RPMI B27+. 8

Harvest of differentiated cardiac cells involved enzymatic digestion, firstly in 0.2% collagenase 9

type I (Sigma) containing 20% fetal bovine serum (FBS) in PBS (with Ca 2+ and Mg 2+ ) at 37°C for 10 1 h, and secondly in 0.25% trypsin-EDTA at 37°C for 10 minutes. Cells were filtered through a 11

100 µm mesh cell strainer (BD Biosciences), centrifuged at 300 x g for 3 min, and resuspended was pipetted into the hCO culture insert and incubated at 37°C with 5% CO 2 for 45 min in order 43

to gel. After gelling, α-MEM GlutaMAX (ThermoFisher Scientific), 10% fetal bovine serum (FBS), 44

200 µM L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma) and 1% 45

Penicillin/Streptomycin (ThermoFisher Scientific) was added. hCO were subsequently cultured 46

in maturation media (MM) (Mills et al., 2017a) with medium changes every 2 to 3 days for 5 47 days (7 days old hCO). To better approximate adult metabolic provisions a 'weaning medium' 48 (WM) was utilized. hCO were cultured in WM containing 4% B27 -insulin, 5.5 mM glucose, 1 1 nM insulin, 200 µM L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate, 1% P/S, 1% 2 GlutaMAX (100x), 33 µg/mL aprotinin and 10 µM palmitate (conjugated to bovine serum 3 albumin in B27) in DMEM without glucose, glutamine and phenol red (ThermoFisher Scientific) 4

with media changes every 2-3 days. 5

The elasticity of the Heart Dyno poles enables the contractile properties to be determined via 7

tracking pole deflection, which directly correlates with force (Mills et al., 2017a) . Videos of 10 8 seconds were made of each hCO with the Nikon ANDOR WD Revolution Spinning Disk 9 microscope (magnification 4x). While imaging, hCO were incubated at 37°C, 5% CO 2 to prevent 10 changes in contractile behaviour. For pacing, hCOs were electrically stimulated at 1 Hz with 5 11 ms square pulses with 20 mA current using a Panlab/Harvard Apparatus Digital Stimulator. on microscope slides using ProLong Glass (ThermoFisher Scientific). 27

Phosphoproteomics experiments were performed with biological triplicates. Phosphopeptides 29

were enriched from 20 pooled hCO, yielding approximately 100 µg of total protein per condition. 30

The high-sensitivity EasyPhos workflow was employed as previously described (Humphrey et  31 al., 2018). Briefly, pooled organoids were lysed in SDC buffer (4% Sodium deoxycholate, 100 32 mM Tris pH 8.5) and immediately heated for 5 min at 95°C. Lysates were cooled on ice, and 33 sonicated with a tip-probe sonicator (50% output power, 30 seconds). An aliquot of lysate was 34 taken and diluted 1:5 in 8 M Urea from which protein concentration was determined by BCA 35 assay (Thermo Fisher Scientific). Aliquots corresponding to 100 µg of protein were 36

subsequently diluted in SDC buffer into a 96-well deep-well plate, reduced and alkylated at 45°C 

Phosphopeptides were loaded onto a 40 cm column fabricated in-house with 75 µM inner 45

diameter fused silica packed with 1.9 µM C18 ReproSil particles (Dr. Maisch GmBH). A column 46 oven (Sonation) was used to maintain column temperature at 60°C, and a U3000 HPLC system 47 (Dionex, Thermo Fisher Scientific) was connected to a Q Exactive HF X benchtop Orbitrap 1 mass spectrometer (Thermo Fisher Scientific) with a NanoSpray Flex ion source (Thermo 2

Fisher Scientific). For all samples, peptides were separated using a binary buffer system of 3 0.1% (v/v) formic acid (buffer A) and 80% (v/v) acetonitrile/0.1% (v/v) formic acid (buffer B). 4

Peptides were eluted at a flow rate of 400 nl/min and separated with a gradient of 3 -19% 5

buffer B over 40 minutes, followed by 19 -41% buffer B over 20 minutes, and peptides were 6

analysed with a full scan (350 -1,400 m/z; R=60,000 at 200 m/z) at a target of 3e6 ions, 7

followed by up to ten data-dependent MS2 scans using HCD (target 1e5; max. IT 50 ms; and filtering steps were repeated twice. All steps of the homogenization were performed on ice. 24

The filtered homogenate was centrifuged at 1500 x g for 5 min at 4 o C. Nuclei pellets were then 25 re-suspended in PBS. A fraction of resuspended nuclei were then stained with Hoechst33324 26 nuclear stain (1:500 dilution) and counted on a haemocytometer under fluorescent microscope. 27

The nuclei were then re-centrifuged (1500 x g for 5 min at 4°C) and resuspended at a density to 28 load ~5,000 nuclei per sample. Cells were loaded into the Chromium Controller (10X Genomics) 29

for gel bead emulsion (GEM) formation. Library preparation was conducted according to the 30 manufacturer's recommended protocol using the Chromium Next GEM Single Cell 3' GEM, 31

Library & Gel Bead Kit v3.1. Libraries were sequenced on the NextSeq 500/550 v2 (Illumina) 32

with 150 bp reads and were sequenced to ~250,000 reads per cell. 33

Raw fastq reads for each sample were processed using CellRanger v3.1.0. Default options 34

were used with CellRanger and a custom made pre mRNA reference using GRCh38 v3.0.0 was 35 used to map the reads and for count quantification with the CellRanger counts tool. Following 36 this, the counts were then aggregated together to create a single matrix that contained all the 37 samples. Reads from the single nuclei sequencing data were aligned to a human pre-mRNA 38

GRCh38 reference genome. All pre-processing and filtering steps of the datasets were 39 subsequently carried out via the Python package Scanpy 40

(https://scanpy.readthedocs.io/en/stable/) (Wolf et al., 2018) . Briefly, there was an initial filtering 41

step for genes that are expressed in 3 or more cells and cells with at least 200 detected genes, 42

subsequently removing cells displaying high expression of mitochondrial genes using a cut-off 43 of 4%. We then filtered out cells that had a count depth with a threshold of under 2,000 and 44

higher than 40,000 to remove debris and potential doublets. Gene expression was subsequently 45 normalized for each cell by total expression, scaled by 10,000 and log scaled. Highly variable 46

genes were then identified for clustering. Leiden clustering with an initial resolution of 0.2 was 47 performed to identify clusters within the data. A published human cardiac snRNA-seq dataset 48 was then used to identify overlap of marker gene sets for main human heart cell types (e.g. 1 cardiomyocytes, fibroblasts, epicardium, pericytes, etc) with the clusters of our dataset, and 2

were labelled accordingly (Tucker et al., 2020) . Further refined clustering was carried out on 3 specific clusters that showed overlap of more than one of the various heart cell types. 4

Visualization of the datasets was primarily carried out using nonlinear dimensionality reduction 5 UMAP plots (Becht et al., 2019) . In the snRNA-seq we note the lower than expected percentage 6 of non-myocytes and the loss of endothelial cells (Mills et al., 2017a; Voges et al., 2017) , 7

indicating the protocol requires further optimization for hCO samples. 8 hCO comparison to bulk nuclei RNA sequencing data for PCA 9

Nuclear RNA-seq dataset generated from sorted cardiomyocyte nuclei at two stages (fetal and Additionally, ribosomal and mitochondrial genes as well as pseudogenes, and genes with no 19

annotation (Entrez Gene identification) were removed before normalization and statistical 20

analysis. 21

Principal component analysis (PCA) performed using the intersection of the 25% most highly 22

variable genes of the snRNA-seq dataset and genes expressed in the bulk samples. Each of the 23 two datasets were log transformed and scaled separately before running the dimensionality 24 reduction method. 

To determine factor effects, second order OLS linear regression was performed across all 1 relevant samples using binary predictors (cytokine presence/absence) with force, 2 relaxation/activation times as the outcome variables. p-values were determined using two-tailed 3 t-tests. Normality (Shipiro-Wilks), heteroskedasticity (Breusch-Pagan), linearity (Harvey-Collier), 4 multicollinearity (condition no.) and skewness/kurtosis (Jarque-Bera) were all checked with the 5 respective tests. The coefficient of determination, R^2 (adjusted), was used to determine 6 goodness of fit. 7

Female K18-hACE2 mice were lightly anesthetized using isoflurane and 50 µl of SARS-CoV-2 9

at 5 x 10 4 TCID50 per mouse was administered via intranasal inoculation (i.n. closely monitored and checked hourly for signs of sepsis. 21

Serum cytokine levels (Ifn-γ, Il-1β and Tnf) were determined with a CBA Flex Set Multiplex 23

Cytokine Bead Array (BD Biosciences). 24

Cardiac function was assessed using a Vevo 2100 ultrasound system fitted with a MS550D 26

transducer, which has a 40 MHz center frequency (Fujifilm Visualsonics). Depilated mice were 27 anaesthetized by isoflurane inhalation (1.5% at 1 L oxygen / min) delivered via a nose cone, 28

kept warm on a heated stage, with respiration and heart rate monitored on ECG pads. B Mode 29

images of the left ventricle were obtained from three short-axis views (proximal, mid and distal 30 positions) and one parasternal long-axis view. Cardiac function parameters were calculated 31

using the Simpson's tool in Vevolab analysis software v3.2.6 (Fujifilm Visualsonics). Briefly, the 32 endocardial areas were traced from all three short-axis views, and the length of the ventricle 33 was determined, in systole and diastole. These measurements were used to calculate ejection 34 fraction. 35

Human CNTI ELISA (RayBiotech), IFN-γ (RnD Systems) and BNP ELISA (Abcam) was used as 37 per manufacturer's instructions. 38

Protein from 2D hPSC-cardiac cell cultures was extracted using RIPA lysis buffer supplemented 40

with protease inhibitor cocktail (Roche Membranes were washed 5 times 3 minutes in PBS with 0.5% Tween, prior to incubation with 4

IRDye® secondary antibodies (1:10000 for IRDye® 800CW Goat anti-Mouse IgG Secondary 5

Antibody, 926-32210, and 680RD Donkey anti-Goat IgG Secondary Antibody, LI-COR 6

Biotechnology, 925-68074) for 1 h at room temperature. Membranes were washed thoroughly (5 7

x 3 min in PBS + 0.5% Tween) and were then imaged on a LI-COR Odyssey® CLx. 8

Densitometry was performed using ImageStudio Lite (version 4). 9

Flow Cytometry for ACE2 and SARS-CoV-2 spike binding assays 10 hPSC-cardiac cells were differentiated as above, then plated at 100,000 per cm 2 For SARS-CoV-2 binding assays the following was used for control, Binding Buffer only, and 27 assay 1 µg rSARS-CoV-2 Spike RB (per ~100,000 cells) and 1:200 anti-human CD90 (all RnD 28

Systems) and were incubated for 60 min at 4°C in binding buffer. The cells were then washed in 29

Binding Buffer, centrifuged at 300 x g for 3 min and supernatant removed. Both conditions were 30 then incubated with 1:400 F(ab')2-goat anti-human IgG Fc secondary antibody conjugated to 31

Alexa Fluor 488 and 1:400 goat anti-mouse IgG secondary antibody conjugated to Alexa Fluor 32 555 (both ThermoFisher Scientific) in Binding Buffer for 45 min at 4°C. The cells were then 33 washed in binding buffer, centrifuged at 300 x g for 3 min and supernatant removed. harvested each day and replaced with 500 µl of media. Supernatants were frozen at -80°C until 2 they were titred. Titration was performed in Vero cell monolayers in 96 well plates: inoculated 3 serial 10-fold dilutions in quadruplicate and incubated for 4 days. Cytopathic effect recorded and 4

virus titre in log10 TCID 50 /ml recorded. 5

Imaging 6

For immunostaining cells or hCO were fixed in 4% paraformaldehyde and stained. Cells were 7 stained with primary antibodies Nucleocaspid protein SARS-CoV-2 (1:200, 40143-MM05, Sino 8

Biological) and cardiac troponin T (1:400, ab45932, Abcam) in Blocking Buffer at 4°C for 2 h for 9

2D or overnight for hCO on a rocker. Cells were washed twice with Blocking Buffer and labelled 10 with secondary antibodies goat anti-mouse IgG AlexaFluor 488 (1:400, A-11001) and goat anti-11

rabbit IgG AlexaFluor 555 (1:400, A-21428) and Hoechst3332 (all ThermoFisher Scientific) at 12 4°C for 2 h for 2D or overnight for hCO on a rocker. Cells were again washed with Blocking 13

Buffer twice and then put into PBS and were imaged using a Leica Thunder microscope. 14 Quantitative RT-PCR 15

Performed as described above. supplemented with 2% B-27 Supplement minus vitamin A, 1% GlutaMAX and 1% 23

Penicillin/Streptomycin-All from ThermoFisher Scientific) with Rock inhibitor (Selleck 24

Chemicals) for 24 h. Cardiac cells were then maintained in RPMI + B27 media for an additional 25 2 days, enriched for cardiomyocytes with lactate purification media -DMEM, no glucose, no 26 glutamine, no phenol red supplemented with 1% GlutaMAX and 1% Penicillin/Streptomycin 27 (Thermo Fisher Scientific) and 5 mM Sodium L-Lactate (Sigma Aldrich) for 2 days, and 28

subsequently cultured in MM from day 15 to day 23 post differentiation prior to viral infection. 29

The media was removed from cultures of cardiac myocytes and Vero cells in 24 well plates. 30 Vero cell plates were washed with 1ml of serum free media per well. Media was removed, wells 31

were inoculated with 10 4 TCID 50 of virus (MOI = 0.01) in 100 µl serum free media and incubated 32

for 1 h at room temperature. The inoculum for Vero cells incorporated TPCK-treated Trypsin 33

(Worthington Biochemical Corporation) at 1 µg/ml. Following virus adsorption, the inoculum was 34 removed and replaced with 500 µl media. After ~10 minutes, this was removed and stored at -35 80°C as the day 0 sample. 500 µl per well of media was replenished and plates were incubated 36 at 37°C in 5% CO2. Each day from day 1 through 6 post-infection, 500 µl of culture supernatant 37

was harvested and replenished with 500 µl of media. Supernatants were stored at -80°C till they 38

were titrated. 39

The amount of infectious virus present in the samples was assayed in Vero cell monolayers in 41 96 well plates. Samples inoculated into 4 wells were diluted serially in 10-fold dilutions in serum 42 free media containing 1 µg/ml TCPK-treated Trypsin and incubated for at 37°C in 5% CO2. 43

Cytopathic effect was scored on day 4 post-infection and virus titre expressed in log 10 

TCID 50 /ml. The lower limit of detection was 1.7 log 10 TCID 50 /ml. 45

SOMAScan TM proteomic technology uses Somamers as an affinity reagent (Somalogic Inc.). 2

Plasma samples from 47 patients from each group that received apabetalone or placebo in the 3 ASSURE trial were analysed and LGALS3BP quantified (Nicholls et al., 2016) . 4

Statistics were performed using GraphPad Prism v8 unless noted with the appropriate tests was taken over a period of 10 seconds and is displayed in real time (50 frames/s). Related to 3 Figure 1 . 4

Human cardiac organoids after treatment with cardiac cytokine storm. 5

The video was taken over a period of 10 seconds and is displayed in real time (50 frames/s). 6

Related to Figure 1 . 

MGI: 3028467 K18-hACE2 C57BL/6J mice (strain B6.Cg-Tg(K18-ACE2)2Prlmn/J)

Oligonucleotides Primers for qPCR, see Table KR1 Software and Algorithms Pole tracking analysis

BET bromodomains mediate transcriptional pause release in heart failure

NKX2-5 regulates human cardiomyogenesis via a HEY2 6 dependent transcriptional network

BET bromodomain proteins regulate transcriptional reprogramming in 9 genetic dilated cardiomyopathy

Systems biological assessment of immunity to mild versus 12 severe COVID-19 infection in humans

BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific 15 lamin A/C-deficient mice

CDK8 kinase phosphorylates transcription factor STAT1 to 18 selectively regulate the interferon response

Dimensionality reduction for visualizing single-cell data using UMAP

Cardiac injuries in coronavirus disease 2019 (COVID-23 19)

Bromodomains: a new target class for drug 25 development

MaxQuant enables high peptide identification rates, individualized p.p.b.-27 range mass accuracies and proteome-wide protein quantification

An inflammatory cytokine signature predicts COVID-19 severity 31 and survival

RNA-SeQC: RNA-seq metrics for quality control and process optimization

The ProteomeXchange consortium in 2017: supporting 37 the cultural change in proteomics public data deposition

STAR: ultrafast universal RNA-seq aligner

BET bromodomain inhibition suppresses innate inflammatory and 44 profibrotic transcriptional networks in heart failure

Selective inhibition of BET bromodomains

Androgen Deprivation Therapy Is Associated With Prolongation 16 of QTc Interval in Men With Prostate Cancer

Selective targeting of BD1 and BD2 of the BET proteins in 19 cancer and immuno-inflammation

Distinct epigenetic programs regulate 22 cardiac myocyte development and disease in the human heart in vivo

Clinical Characteristics of Covid-19 in

Impact of paroxetine on proximal 28 β-adrenergic receptor signaling

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Extrapulmonary manifestations of COVID-19

Selective and Potent CDK8/19 Inhibitors Enhance NK-37 Cell Activity and Promote Tumor Surveillance

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary 41 Report. medRxiv

Clinical 43 features of patients infected with 2019 novel coronavirus in Wuhan

Orchestrating high-throughput genomic analysis with Bioconductor

Primitive cardiac cells 1 from human embryonic stem cells

High-throughput phosphoproteomics reveals in 3 vivo insulin signaling dynamics

High-throughput and high-sensitivity 5 phosphoproteomics with the EasyPhos platform

Heat shock protein 10 inhibits lipopolysaccharide-induced 9 inflammatory mediator production

Epigenetic Reader BRD4 (Bromodomain-Containing Protein

Governs Nucleus-Encoded Mitochondrial Transcriptome to Regulate Cardiac Function

Patterns of myocardial injury in recovered troponin-positive COVID-19 17 patients assessed by cardiovascular magnetic resonance. European heart 18 journal

Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression 21 of Tumor Necrosis Factor-&#x3b1

Enrichr: a comprehensive gene set enrichment analysis web 24 server 2016 update

Complete removal of mycoplasma from 26 viral preparations using solvent extraction

Could interferon-gamma be a therapeutic target for treating 28 heart failure?

RSEM: accurate transcript quantification from RNA-Seq data with or 30 without a reference genome

The Sequence Alignment/Map format and SAMtools

featureCounts: an efficient general purpose program for 35 assigning sequence reads to genomic features

Cytokine Storms: Understanding COVID-19

Cutadapt removes adapter sequences from high-throughput sequencing reads

Ultra-High-Throughput Clinical Proteomics Reveals 43 Classifiers of COVID-19 Infection

Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-46 proliferative Compounds Acting via the Mevalonate Pathway

Functional screening in human cardiac organoids reveals a 2 metabolic mechanism for cardiomyocyte cell cycle arrest

Functional screening in human cardiac organoids reveals a 6 metabolic mechanism for cardiomyocyte cell cycle arrest

Illuminating the dark 9 phosphoproteome

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary 12 Atherosclerosis: Results of the Phase 2b

Apabetalone and hospitalization for heart failure in 17 patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Suppression of inflammation by a synthetic histone mimic

COVID-19 and cardiovascular disease: 23 from basic mechanisms to clinical perspectives

Lethality of SARS-CoV-2 infection in K18 human 26 angiotensin-converting enzyme 2 transgenic mice

Generation, expansion and functional analysis of endothelial cells and pericytes derived from human 30 pluripotent stem cells

BRD4 (Bromodomain-Containing Protein 4) 33 Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult 34

Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A 37 Pathologic Study

Outcomes of Cardiovascular Magnetic Resonance 40 Imaging in Patients Recently Recovered From Coronavirus Disease

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and 44 TMPRSS2

Multicellular Transcriptional Analysis of Mammalian Heart Regeneration

Effect of Apabetalone Added to Standard Therapy on 5

Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 6 Diabetes: A Randomized Clinical Trial

COVID-19 8 immune features revealed by a large-scale single cell transcriptome atlas

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

edgeR: a Bioconductor package for differential 14 expression analysis of digital gene expression data

Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With 18

Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 19 10

SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of 22 serine phosphorylation of STAT1 and STAT5 transactivation domains

Recruitment of Stat1 to chromatin is required for interferon-induced serine 26 phosphorylation of Stat1 transactivation domain

Proteomic Evaluation of the Comorbidity-Inflammation 30 Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study

Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after 34 myocardial infarction

Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan

Dynamic Chromatin Targeting of BRD4 Stimulates 44

The Novel Bromodomain and Extraterminal Domain Inhibitor 47

INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies

The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) -4 a Systematic Echocardiographic Study

Transcriptional and Cellular Diversity of the Human Heart. 7 Circulation 0

Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics 9 Data in Cancer Research

Gβγ-independent recruitment of G-protein coupled 13 receptor kinase 2 drives tumor necrosis factor α-induced cardiac β-adrenergic receptor dysfunction

Development of 16 a human cardiac organoid injury model reveals innate regenerative potential

Identifying collagen VI as a target of fibrotic diseases

Proceedings of the National Academy of Sciences of the United States of America

SCANPY: large-scale single-cell gene expression data 23 analysis

Characteristics of and Important Lessons From the Coronavirus 25 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese 26 Center for Disease Control and Prevention

Highlights • Pro-inflammatory factors drive systolic and diastolic cardiac dysfunction • BRD4 activation drives diastolic dysfunction and is blocked by clinically relevant drugs • BET inhibition decreases ACE2 expression and decreases SARS-CoV2 infection